Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer With Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 or huMNC2-CAR22, Specific for a Cleaved Form of MUC1 (MUC1*)
Latest Information Update: 05 Jul 2024
At a glance
- Drugs HuMNC2 CAR44 T-cells (Primary) ; Cyclophosphamide; Fludarabine
- Indications Advanced breast cancer; HER2 positive breast cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Minerva Biotechnologies
Most Recent Events
- 04 Jun 2024 Protocol amended to include changes in inclusion criteria; Based on responses of initial huMNC2-CAR44 patients, inclusion criteria were amended to an Enrichment Trial Design.
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 10 Apr 2024 Results (n=8) assessing the safety and preliminary anti-tumor activity of MUC1* for the treatment of metastatic breast cancers presented at the 115th Annual Meeting of the American Association for Cancer Research